A Phase I/II, Non Randomized, Multicenter, Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-linked Chronic Granulomatous Disease

Trial Profile

A Phase I/II, Non Randomized, Multicenter, Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-linked Chronic Granulomatous Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs NADPH oxidase gene therapy (Primary)
  • Indications Chronic granulomatous disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genethon
  • Most Recent Events

    • 02 Feb 2017 Planned number of patients changed from 20 to 5.
    • 02 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2020.
    • 02 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top